Evidence map›Paper›PMID 41394080›Full record

ArticleBioinformatics advances2025

PSQAN: a pipeline to prioritize novel and biologically relevant transcripts from long-read RNA sequencing.

Siddharth Sethi, Emil K Gustavsson, Harpreet Saini, Mina Ryten

Abstract read
In one paragraph

Article in Bioinformatics advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Siddharth SethiAstex Pharmaceuticals, Cambridge, CB4 0QA, United Kingdom.ORCID https://orcid.org/0000-0002-4398-4295
Emil K GustavssonDepartment of Genetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London, WC1N 1EH, United Kingdom.ORCID https://orcid.org/0000-0003-0541-7537
Harpreet SainiAstex Pharmaceuticals, Cambridge, CB4 0QA, United Kingdom.ORCID https://orcid.org/0000-0002-3733-7657
Mina RytenDepartment of Genetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London, WC1N 1EH, United Kingdom.ORCID https://orcid.org/0000-0001-9520-6957

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Motivation: Long-read RNA sequencing has the potential to accurately quantify transcriptomes and reveal the isoform diversity of disease-causing genes. However, despite the recent advances in analysis tools for transcript discovery, long-read RNA sequencing data is still challenging to analyse, due to the detection of hundreds or even thousands of novel transcripts per gene. Results: Here, we introduce PSQAN, a workflow to help researchers prioritize high-confidence and potentially biologically relevant transcripts associated with candidate genes and make transcript characterization results more interpretable. PSQAN performs a gene-based analysis on characterized transcripts generated by SQANTI3 and TALON. PSQAN re-groups transcripts into easily interpretable categories to facilitate their prioritization, allows transcript-level expression thresholds, and generates visualizations to determine optimal expression thresholds. Overall, we demonstrate that PSQAN is a useful tool which enables users to identify known and novel transcripts of potential biological importance. Availability and implementation: PSQAN is an analysis workflow implemented in Snakemake and R and is licensed under the GNU General Public License version 3. The source code and documentation of this tool is available at https://github.com/sid-sethi/PSQAN.

Identifiers

PMID41394080
PMCPMC12701792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.